Thrombosis Research Institute LondonEmmanuel Kaye BuildingManresa RoadChelseaLondon SW3 6LR

Media ContactRae HobbsRHobbs@tri-london.ac.uk+44 (0) 7753 825 217

GARFIELD-VTE Data Impresses at ISTH 2017

There was standing room only when the first data from the GARFIELD-VTE Registry was

presented during the Thrombosis Research Institute (TRI) satellite symposium on Wednesday

12th July at the International Society on Thrombosis and Haemostasis (ISTH) Congress 2017.

The congress took place in Berlin from Saturday 8th to Thursday 13th July, during which the

GARFIELD-VTE data was also showcased at an oral presentation and three poster

presentations – one of which was awarded an ISTH Congress rosette – and on the TRI

exhibition booth.

The booth showcased the work of not just the GARFIELD-VTE Registry but all of the registries

and studies conducted by the TRI, including the Frontline 2 thrombosis and cancer survey

http://frontline2.tri-london.ac.uk/.

Page 1 of 5

Thrombosis Research Institute LondonEmmanuel Kaye BuildingManresa RoadChelseaLondon SW3 6LR

Media ContactRae HobbsRHobbs@tri-london.ac.uk+44 (0) 7753 825 217

On the Monday, Professor Weitz’s poster showed the differences observed between the clinical

characteristics of VTE in patients with and without active cancer or a history of cancer. His

conclusion was that the majority of VTE patients with cancer are treated with low molecular

Page 2 of 5

Thrombosis Research Institute LondonEmmanuel Kaye BuildingManresa RoadChelseaLondon SW3 6LR

Media ContactRae HobbsRHobbs@tri-london.ac.uk+44 (0) 7753 825 217

weight heparin (LMWH) monotherapy, in keeping with guidelines, although some are prescribed

direct oral anticoagulants (DOACs).

On the Tuesday, there were two posters in the same poster session. Professor Turpie

presented 6-months outcomes data showing that death was the most frequent major adverse

outcome in patients with VTE, with half being cancer-related. The last of the posters, presented

by Professor Sylvia Haas, was by no means the least. Entitled ‘Anticoagulation treatment

patterns of venous thromboembolism in GARFIELD-VTE patients’, it was awarded a rosette for

being a top scoring poster. In her conclusion, Professor Haas explained that there was a clear

shift from conventional parenteral plus VKA treatment in the first 30 days towards DOACs in the

following 5 months, raising the question about whether DOACs have become the new standard

of care for chronic anticoagulation.

Page 3 of 5

Thrombosis Research Institute LondonEmmanuel Kaye BuildingManresa RoadChelseaLondon SW3 6LR

Media ContactRae HobbsRHobbs@tri-london.ac.uk+44 (0) 7753 825 217

Professors Turpie and Haas were joined by Professor Mantovani during the poster session and

all three provided their perspectives on the GARFIELD-VTE data in discussions with delegates

who came to view the posters.

On the penultimate day of ISTH 2017, members of the GARFIELD-VTE Steering Committee

presented the registry’s initial insights on the management of VTE. In a room filled beyond

capacity, topics included: characterising patients and their treatments, anticoagulation

management strategies, cancer-associated thrombosis and outcomes in the real world.

Immediately after the satellite symposium, Dr Ageno spoke about the clinical characteristics and

management of 10,677 patients with a confirmed diagnosis of DVT and/or PE enrolled in

GARFIELD-VTE at an oral presentation. The crowd took great interest in Dr Ageno’s

presentation, as he indicated that there is a wide heterogeneity among VTE patients. He

concluded that there should be a personalised approach to therapy.

Page 4 of 5

Thrombosis Research Institute LondonEmmanuel Kaye BuildingManresa RoadChelseaLondon SW3 6LR

Media ContactRae HobbsRHobbs@tri-london.ac.uk+44 (0) 7753 825 217

Even at this early stage of data presentation, GARFIELD-VTE has made an impression in the

thrombosis world, and ISTH 2017 was an excellent opportunity to showcase the initial findings

and whet the appetites of people with an interest in venous thromboembolism. We look forward

to sharing further insights and two-year outcomes data with you at ISTH 2019, in Melbourne,

Australia.

###

Page 5 of 5